NCT05457894CompletedPhase 3
Randomized, Double-blind, Comparative, Controlled Trial of Tolerability, Reactogenicity, Safety and Immunogenicity of Flu-M [Inactivated Split Influenza Vaccine] in Pregnant Women During the 2nd - 3rd Trimester
St. Petersburg Research Institute of Vaccines and Sera5 sites in 1 country207 target enrollmentStarted: January 23, 2020Last updated:
Conditions
Trial Snapshot
- Phase
- Phase 3
- Status
- Completed
- Enrollment
- 207
- Locations
- 5
- Primary Endpoint
- Change from Baseline Seroconversion rate at day 21 after vaccination
Study Overview
Brief Summary
Comparative study of tolerability, reactogenicity, safety and immunogenicity Flu-M [Inactivated Split Influenza Vaccine] vs. the Ultrix® vaccine for the prevention of influenza in pregnant women in the 2nd-3rd trimesters of pregnancy
Detailed Description
This is a randomized, double-blind, comparative, controlled trial. A design with a control group treated with Ultrix®, inactivated influenza vaccine, was chosen to obtain objective findings.Trial population: healthy women aged 18 to 35 years during the 2nd and 3rd trimesters of pregnancy. Subjects were randomized into 4 groups in a ratio of 1:1:1:1, 50 subjects per group.
Study Design
- Study Type
- Interventional
- Allocation
- Randomized
- Intervention Model
- Parallel
- Primary Purpose
- Prevention
- Masking
- Double (Participant, Investigator)
Eligibility Criteria
- Ages
- 18 Years to 35 Years (Adult)
- Sex
- Female
- Accepts Healthy Volunteers
- Yes
Inclusion Criteria
- •Presence of signed Informed Consent of the female patient to participate in the trial
- •Healthy women aged 18 to 35 years in their 2nd and 3rd trimesters of pregnancy with gestational age of no more than 32 weeks
- •Singleton pregnancy progressing normally
- •No contraindications for vaccination
- •Pregnant women that are able to fulfill the requirements of the protocol (i.e., fill out the Self-Observation Diary, come to follow-up visits)
- •The investigator is given the opportunity to collect data about somatic, infectious, and allergic diseases within at least 3 months from vaccination (one or more calls from the clinical investigator or visits per month (as needed))
Exclusion Criteria
- •Body temperature above 37°С
- •History of influenza or previous influenza vaccination during 6 months before the screening
- •History of allergic reactions to chicken protein
- •Allergic reactions to vaccine components or any previous vaccination
- •Gestational toxicosis
- •Any disorders of pregnancy
- •Thyroid disorders
- •Bronchial asthma
- •Clotting disorders
- •1, 2 type diabetes mellitus
- •High risk of fetal chromosomal abnormalities (individual risk of at least 1/100) in the 1st trimester of pregnancy and/or the detection of fetal congenital anomalies / developmental defects in the 1st, 2nd, and 3rd trimesters of pregnancy
- •Strong reaction (temperature above 40 °C, hyperemia or edema more than 8 cm in diameter) or complications (collapse or shock-like condition) that developed within 48 hours from prior vaccination; convulsions accompanied or not accompanied by a fever due to any prior vaccination
- •Acute infectious or non-infectious diseases less than 4 weeks before the screening, exacerbation of chronic diseases (the vaccination can be carried out after recovery or in the period of remission)
- •Immunomodulatory therapy, including immune-enhancing, immunosuppressive therapy (corticosteroids, cytotoxic and radioactive drugs) in the 6 months preceding the trial
- •Any other contraindications against vaccination according to the investigator.
- •Leukemia, cancer or a positive reaction to HIV infection, hepatitis B and C, syphilis in the medical history
- •Volunteers who received immunoglobulin or blood products within the last three months before the trial
- •History of Guillain-Barré syndrome (acute polyneuropathy)
- •Autoimmune diseases
- •Any confirmed or suspected immunosuppressive or immunodeficiency condition
- •Respiratory, cardiovascular failure, impaired liver or kidney function.
- •Severe birth defects or serious chronic diseases, including any clinically significant chronic diseases of lungs, kidneys, cardiovascular, nervous system, psychiatric diseases or metabolic disorders, confirmed by medical history or objective examination
- •Vaccination with any vaccine less than 30 days before the screening or scheduled vaccination with any vaccine within 30 days from vaccination with the trial vaccines
- •The woman is/was a patient of a tuberculosis dispensary and/or narcological dispensary and/or neuropsychiatric dispensary
- •Chronic alcohol abuse and/or use of drugs in the past history
- •Participation in another clinical trial during the last 3 months
Outcomes
Primary Outcomes
Change from Baseline Seroconversion rate at day 21 after vaccination
Time Frame: Days 0 (screening), 21
The relative number of vaccinees, whose titer of hemagglutinin inhibiting antibodies has increased by more than 4 times vs. baseline among all immunoprotective persons. Antibodies to influenza B, А (H1N1), А (H3N2) viruses Seroconversion rate ≥ 40%
Change from Baseline Seroconversion factor at day 21 after vaccination
Time Frame: Days 0 (screening), 21
An increase in the geometric mean titers of hemagglutinin inhibiting antibodies on Day 21 vs. baseline, expressed in multiplicity of increase. Antibodies to influenza B, А (H1N1), А (H3N2) viruses Seroconversion factor ≥ 2.5
Change from Baseline Seroprotection rate at day 21 after vaccination
Time Frame: Days 0 (screening), 21
The percentage of vaccinees who have an antibody titer of more than 1:40 by Day 21 after vaccination. Antibodies to influenza B, А (H1N1), А (H3N2) viruses Seroprotection rate ≥ 70%.
Secondary Outcomes
- Number of participants with abnormal changes in physical examination data(Days 0-7, day 21)
- Incidence of AEs and SAEs associated with vaccination(Day 1 (30 minutes, 3 and 5 hours after vaccination), days 2-21)
- Number of participants with abnormal changes of neurological examination data(Days 0-7, day 21)
- Number of participants with clinically significant abnormalities - Biochemical blood test (BBT)(Days 0 (screening), 3, 21)
- Number of participants with abnormal changes data obtained from examinations by immunologist-allergist(Days 1-7, day 21)
- Number of participants with abnormal changes in the ultrasound data assessment of fetus and uterus(Days 0 (screening), 21)
- Number of participants with abnormal changes in vital signs - Blood pressure (BP)(Days 0-7, day 21)
- Number of participants with abnormal changes in vital signs - Heart rate (HR)(Days 0-7, day 21)
- Number of participants with abnormal changes in vital signs - Respiratory rate (RR)(Days 0-7, day 21)
- Number of participants with abnormal changes in vital signs - Body temperature(Days 0, 1 (10 minutes before vaccination, 30 minutes and 2 and 5 hours after vaccination), days 2-7, day 21)
- Incidence and severity of local post-injection reactions(Day 1 (30 minutes, 3 and 5 hours after vaccination), days 2-21)
- Number of participants with clinically significant abnormalities - Complete blood count (CBC)(Days 0 (screening), 3, 21)
- Number of participants with clinically significant abnormalities - Urinalysis(Days 0 (screening), 3, 21)
- Number of participants with abnormal changes of total IgE(Days 0 (screening), 3, 21)
- Incidence and severity of systemic post-injection reactions(Day 1 (30 minutes, 3 and 5 hours after vaccination), days 2-21)
- Number of participants with abnormal changes data obtained from examinations by obstetrician-gynecologist(Days 0-7, day 21)
Investigators
Study Sites (5)
Loading locations...
Similar Trials
Completed
Phase 3
Tolerability, Safety and Immunogenicity Trial of the Flu-M® Inactivated Vaccine in Volunteers Aged 18 to 60 YearsFlu, HumanInfluenzaNCT05312294St. Petersburg Research Institute of Vaccines and Sera654
Completed
Phase 3
Trial of Tolerability, Safety and Immunogenicity of the Flu-M Vaccine in Children Between 6 Months and 9 Years OldInfluenza, HumanVaccinesInfection VaccinationNCT05470582St. Petersburg Research Institute of Vaccines and Sera1,066
Completed
Phase 2
Tolerability, Safety and Immunogenicity Trial of the Flu-M Quadro, Tetravalent Inactivated Split Influenza VaccineInfluenza, HumanInfluenza Viral InfectionsVaccine ReactionInfluenzaInfection VaccinationNCT05869201St. Petersburg Research Institute of Vaccines and Sera450
Completed
Phase 1
The Objectives of This Study Are Study the Safety, Reactogenicity and Obtain Preliminary Data on the Immunogenicity of Flu-M Quadro, 4-valent Inactivated Split Influenza Vaccine, in Healthy VolunteersInfluenzaNCT05152017St. Petersburg Research Institute of Vaccines and Sera75
Completed
Phase 2
Trial of the Reactogenicity, Safety and Immunogenicity of the Flu-M Vaccine Manufactured by FSUE SPbSRIVS FMBAInfluenzaNCT05297994St. Petersburg Research Institute of Vaccines and Sera400